ArticleRevista peruana de medicina experimental y salud publica2026
Ceftazidime-avibactam and aztreonam as a therapeutic alternative in two episodes of bacteremia due to Stenotrophomonas maltophilia after allogeneic hematopoietic stem cell transplantation: case report.
Article in Revista peruana de medicina experimental y salud publica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aztreonam-Avibactam Successfully Treated SevereJournal of blood medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection due to Stenotrophomonas maltophilia represents a therapeutic challenge in immunocompromised patients, especially during hematopoietic recovery after hematopoietic stem cell transplantation (HSCT). The use of trimethoprim-sulfamethoxazole (TMP-SMX), the first-line antimicrobial, is contraindicated due to its hematological toxicity. We present the case of a patient undergoing haploidentical HSCT who developed two episodes of bacteremia due to S. maltophilia on days +20 and +49. Given the contraindication of TMP-SMX due to severe myelosuppression, the combination of ceftazidime-avibactam and aztreonam was used as an alternative treatment, achieving clinical resolution in both episodes. The patient remained stable until day +100; however, he experienced graft failure and died on day +107 due to infection with Pseudomonas aeruginosa producing VIM-type carbapenemase. This case shows that the use of ceftazidi-me-avibactam plus aztreonam can be useful against S. maltophilia infections in post-HSCT patients with contraindications for the use of TMP-SMX.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.